This trial is designed to investigate the effects of the patient's own stem cells in myocardial ischemia. The trial is being conducted by the Odessa National Medical University and seeks to enrol 50 patients with ischaemic heart disease. The trial aims to investigate whether the patient's own blood stem cells (CD34+ stem cells) improves outcomes. Participants will receive either conventional therapy (control group) or conventional therapy and stem cells (experimental group). In the experimental group, the stem cells will be injected into the heart muscle. Participants will be monitored for any complications and any changes in heart function (specifically global left ventricular ejection fraction and regional wall motion score index) three and six months after treatment. The study commenced in 2012 and is expected to run until January 2015.